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The aim of this study was to develop an in vitro tool for predicting drug solubility and 19 
dissolution in intestinal fluids of patients with Celiac disease (CED). Biorelevant media for 20 
patients with CED were developed based on published information and a Design of Experiment 21 
(DoE) approach. The CED biorelevant media were characterised according to their surface 22 
tension, osmolality, dynamic viscosity and buffer capacity. By performing solubility studies of 23 
six drugs with different physicochemical properties in CED media, we aimed to identify drugs 24 
at high risk of altered luminal solubility in CED patients. Identified differences in CED patients 25 
compared to healthy subjects were related to a higher concentration of bile salts, lecithin and 26 
cholesterol and included as factors in the DoE resulting in 8 CED biorelevant media. 27 
Differences in media properties were observed for the surface tension between biorelevant 28 
media based on CED patients and healthy subjects. In terms of solubility, only a minimal effect 29 
of CED on the solubility of the hydrophilic neutral compound azathioprine was observed. For 30 
neutral moderately lipophilic compounds (budesonide, celecoxib) a higher surfactant 31 
concentration resulted in most cases in a higher drug solubility, while it was specific to each 32 
drug whether this was mainly driven by bile salts or lecithin. In comparison, drug solubilisation 33 
of ionisable compounds with moderate to high lipophilicity was less impacted by CED 34 
differences. The developed biorelevant CED media serve as in vitro tool to identify the main 35 
media factors impacting on drug solubility. 36 
Keywords 37 
Gastrointestinal diseases; Celiac disease; Biorelevant media; Physicochemical properties; 38 
Solubility   39 
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1. Introduction 40 
Celiac disease (CED) is a chronic auto-inflammatory disease induced by an intolerance to 41 
dietary gluten, a storage protein of wheat, rye, barley and oats. Approximately 1% of the 42 
population is affected by CED and its aetiology is a combination of genetic predisposition and 43 
environmental factors (e.g., breastfeeding, time of gluten introduction and the microbiota) 44 
(Koehler et al., 2014). CED mainly affects the small intestine resulting in gastrointestinal (GI) 45 
symptoms such as bloating, diarrhoea, malabsorptive symptoms and weight loss. Additionally, 46 
CED patients can present extra-intestinal symptoms such as dermatitis herpetiformis, anaemia 47 
or osteoporosis (Leffler et al., 2015). The diagnosis involves serological testing for 48 
autoantibodies (anti-tTG, anti-EMA) and an endoscopic biopsy (Turner et al., 2015). 49 
Depending on the damage to the small intestine, the disease can be classified in different 50 
disease grades based on histological findings such as crypt hyperplasia, the constitution of the 51 
villi and the intra-epithelial lymphocytes in the jejunum and duodenum (Oberhuber et al., 52 
1999). For the treatment of CED, patients need to adhere to a gluten-free diet, the only known 53 
effective treatment to date, since the reintroduction of dietary gluten results in a relapse of the 54 
disease (Gottlieb et al., 2015). More treatment options are expected to emerge in the near future, 55 
since several new active pharmaceutical ingredients have reached clinical phases of drug 56 
development in recent years (Gottlieb et al., 2015). 57 
Patient convenience dictates that oral administration is the preferred route of drug 58 
administration for most drugs. Consequently, patients with CED are likely to be treated with 59 
orally administered drug products for concomitant conditions or extra-intestinal manifestations 60 
of CED. Since oral drug administration is, apart from drug and formulation properties, 61 
dependent on gastrointestinal physiology, pathophysiological changes in CED could affect 62 
drug safety and efficacy. GI diseases can affect various processes involved in oral drug delivery 63 
e.g., drug release from the formulation, drug dissolution, permeation through the GI membrane 64 
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and gut or hepatic metabolism (Effinger et al., 2019). Altered drug absorption in CED patients 65 
compared to healthy subjects has previously been attributed to a reduced small intestinal 66 
surface area, a different intestinal CYP enzyme abundance, a higher jejunal permeability and 67 
differences in gastric emptying (Tran et al., 2013). 68 
So far, there is only a small number of drugs for which drug product performance has been 69 
investigated in CED patients and these studies included only a small number of patients (Tran 70 
et al., 2013). Due to the high costs of clinical trials, it is expected that in the future investigations 71 
in CED patients will remain rare.  72 
For poorly soluble drugs, drug absorption can be limited by the dissolution rate or the solubility 73 
of the drug in gastrointestinal fluids (Amidon et al., 1995). If this is the case, in vitro release 74 
and dissolution testing can be used as surrogate for a drug’s in vivo performance (Amidon et 75 
al., 1995). To simulate closely the conditions present in the GI tract, biorelevant media were 76 
developed mimicking the composition of the gastrointestinal fluids of healthy subjects (Galia 77 
et al., 1998; Jantratid et al., 2008; Markopoulos et al., 2015; Vertzoni et al., 2010; Vertzoni et 78 
al., 2005). The composition of the gastrointestinal fluids can be altered in patients with GI 79 
disease and therefore, in vitro dissolution and solubility studies with biorelevant media adapted 80 
to pathophysiological conditions could result in better predictions of drug product performance 81 
in patient populations (Effinger et al., 2019). 82 
This study aims to identify drugs at risk of altered solubility in GI fluids of CED patients. 83 
Biorelevant media for patients with CED representative of the small intestinal fluid in the fasted 84 
and fed state were developed. Information from literature was collected to identify differences 85 
in the composition of luminal contents of patients with CED compared to healthy subjects. 86 
Biorelevant media for CED patients were developed based on biorelevant media for healthy 87 
subjects and a Design of Experiment (DoE) approach by integrating the identified differences 88 
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as factors with two levels. Subsequently, the CED biorelevant media were characterised in 89 
terms of surface tension, osmolality, buffer capacity and dynamic viscosity. Additionally, the 90 
solubility of six compounds with different physicochemical properties (including azathioprine, 91 
budesonide, celecoxib, dipyridamole, loperamide and sulfasalazine), in the developed 92 
biorelevant media based on CED patients and healthy subjects was determined. 93 
2. Materials 94 
Acetic acid High Performance Liquid Chromatography (HPLC) grade, chloroform, sodium 95 
oleate, budesonide, phosphoric acid and sodium hydroxide were purchased from Sigma-96 
Aldrich Company Ltd., Dorset, England. Sulfasalazine, loperamide hydrochloride, 97 
dipyridamole, celecoxib, azathioprine, methanol HPLC grade and acetonitrile HPLC grade 98 
were purchased from VWR International Ltd, Lutterworth, UK. Sodium chloride, 99 
trifluoroacetic acid (TFA), potassium dihydrogen orthophosphate, dimethyl sulfoxide and 100 
maleic acid were used from Fisher Scientific UK Ltd., Loughborough, England. Other 101 
chemicals used included sodium taurocholate (Prodotti Chimici Alimentari S.P.A., Basaluzzo, 102 
Italy), egg lecithin–Lipoid EPCS (Lipoid GmbH, Ludwigshafen, Germany), glyceryl 103 
monooleate–Rylo Mg 19 (Danisco, Brabrand, Denmark) and cholesterol (95%, Acros 104 
Organics, Geel, Belgium). Water was ultra-pure (Milli-Q) laboratory grade. 105 
3. Methods 106 
3.1. Media development 107 
3.1.1. GI physiological differences in CED compared to healthy subjects 108 
To identify differences in the composition of GI fluids of untreated CED patients compared to 109 
healthy subjects, a literature search was performed. Since to date the GI fluids of CED patients 110 
have not been directly characterised, studies investigating parameters that most likely impact 111 
on GI fluids were considered. 112 
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The bile flow and biliary lipid output has previously been measured in untreated CED patients 113 
and healthy subjects during a constant infusion of a liquid formula diet using a duodenal 114 
intubation technique (Vuoristo and Miettinen, 1985). Biliary lipid outputs such as cholesterol, 115 
bile acids and phospholipids could be estimated in comparison to the dilution of a marker 116 
(polyethylene glycol 4000). The bile flow was with 232±29 mL/h (mean ± SD) significantly 117 
higher in CED patients compared to 132±24 mL/h in healthy subjects (Student’s t-test, p<0.05). 118 
The biliary cholesterol output normalised to the body weight was significantly increased in 119 
CED patients (0.82±0.10 vs 0.43±0.06 mg/kg*h, p<0.02). Similarly, the biliary output of 120 
phospholipids was also highly increased in CED patients compared to healthy subjects 121 
(0.26±0.05 vs 0.08±0.02 mg/kg*h, p<0.02). Additionally, a higher bile acid output was 122 
observed in CED patients (9.28±1.65 vs 4.64±0.45 mg/kg*h). In accordance, it was observed 123 
that the bile salt pool is three times higher in CED patients compared to healthy subjects, which 124 
could be related to a very effective ileal reabsorption of bile acids or a sluggish contraction of 125 
the gall bladder (Low-Beer et al., 1973). Since our study was based on untreated CED patients 126 
(not adhering to a gluten-free diet), dietary differences between CED patients and healthy 127 
subjects were not considered. 128 
3.1.2. Development of CED media with Design of Experiment 129 
The development of biorelevant media for CED patients followed a DoE approach and CED 130 
biorelevant media representative of the small intestinal fluid in the fasted and fed state were 131 
developed. Biorelevant media previously developed based on healthy subjects were used as the 132 
basis for CED biorelevant media and included Fasted-State Simulated Intestinal Fluid-Version 133 
2 (FaSSIF-V2) and Fed-State Simulated Intestinal Fluid-Version 2 (FeSSIF-V2) (Jantratid et 134 
al., 2008). According to the identified differences described in Section 3.1.1, biorelevant media 135 
based on healthy subjects were modified by including the differences as factors in the 136 
experimental design. For both prandial states, the integrated factors in the experimental design 137 
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were the concentration of bile salts, lecithin and cholesterol. Since the biliary secretion is the 138 
main source of bile salts, lecithin and cholesterol present in the intestinal fluids, a direct 139 
correlation between biliary output and intestinal concentration was assumed. Since the three 140 
parameters were not directly measured in the GI fluids, an indirect percental approach was 141 




∗ 𝑥𝐻−𝐵𝑀          (1) 143 
where 𝑥𝐶𝐸𝐷−𝐵𝑀 is the high level of the factor in CED media, 𝑦𝐶𝐸𝐷 and 𝑦𝐻 are the median of 144 
the corresponding biliary output observed in CED patients and healthy subjects, respectively 145 
and 𝑥𝐻−𝐵𝑀 is the level of the factor in biorelevant media based on healthy subjects. 146 
The three factors were integrated with two levels in the experimental design, a low and a high 147 
level. The low level was based on the concentration in biorelevant media based on healthy 148 
subjects (Table 1) and the high level corresponded to the median percentage of the respective 149 
concentration in the healthy medium. For cholesterol, the low level concentration was based 150 
on the median concentration of cholesterol observed in human intestinal fluid as observed by 151 
Riethorst et al. (2016) [fasted state: 0.08 mM, fed state: 0.57 mM], since cholesterol is not a 152 
component of FaSSIF-V2 and FeSSIF-V2.  153 
The DoE was performed with Statgraphics Centurion 18 (Statpoint Technologies Inc., VA, US) 154 
with a full factorial design for CED intestinal biorelevant media for the fasted and fed state. 155 
An overview of the DoE is given in Figure 1. Biorelevant media were prepared as previously 156 
described with an additional step of adding cholesterol (Jantratid et al., 2008). The cholesterol 157 
solution (50 mg/mL in chloroform) was mixed with a lecithin solution (100 mg/ml in 158 
dichloromethane) using a magnetic stirrer, before being added to the bile salt/buffer mixture 159 
and driven off using a rotary evaporator Büchi Rotovapor R-114 (Büchi Labotechnik, Flawil, 160 
Switzerland) according to the published protocol. The osmolality of CED media was set to the 161 
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value in the corresponding biorelevant medium based on healthy subjects by adjusting the 162 
concentration of sodium chloride. 163 
3.1.3.    Media characterisation 164 
Surface tension, osmolality, dynamic viscosity and buffer capacity of biorelevant media 165 
previously developed based on healthy subjects and newly developed for CED patients were 166 
measured in triplicate. The results are reported as mean with standard deviation. 167 
3.1.3.1. Surface tension 168 
Surface tension measurements were performed at room temperature with a ring tensiometer 169 
(Sigma 700 Force tensiometer, Attension, UK) using approximately 10 mL of each medium, 170 
placed in a glass vessel with a diameter of 46 mm. A platinum Du Noüy ring was lowered 171 
below the meniscus of the medium. Subsequently, by pushing and pulling the ring through the 172 
surface of the medium, the force exerted by the meniscus was measured and related to the 173 
surface tension of the medium (Butt et al., 2004). 174 
3.1.3.2. Osmolality 175 
Osmolality was determined with an Advanced Instruments Inc. micro-osmometer Model 3300 176 
(Norwood, MA, US). Therefore, the freezing-point depression of a 20 µl sample was measured 177 
with a high-precision thermistor following the supercooling and induced crystallisation of the 178 
sample. 179 
3.1.3.3. Dynamic viscosity 180 
The dynamic viscosity at 37⁰C was measured with a Bohlin Rheometer C-VOR (Malvern 181 
instruments, UK). Therefore, a cone-plate measuring system, including a rotating upper cone 182 
(4°, 40mm) and a fixed lower plate with the medium contained between them, was used. The 183 
shear rate was measured while twenty different shear stresses, logarithmically distributed in 184 
the range of 0.05 to 0.15 Pa, were exerted on the sample of the medium. The ratio of shear 185 
stress to shear rate corresponds to the dynamic viscosity. 186 
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3.1.3.4. Buffer capacity 187 
Buffer capacity was determined using a potentiometric titration method. Therefore, small 188 
volumes of 0.5 M hydrochloric acid were added to 10 mL of sample until a change of one pH 189 
unit was recorded by a Mettler Toledo SevenCompact S220 pH meter (Schwerzenbach, 190 







                    (2) 192 
where Vacid is the volume of the acid added, Vs is the volume of the sample and ΔpH 193 
corresponds to the change in pH (Rabbie et al., 2015). 194 
3.2. Compound selection 195 
For the solubility studies, low soluble compounds belonging to Biopharmaceutics 196 
Classification System (BCS) class II (low solubility, high permeability) or IV (low solubility, 197 
low permeability) were selected as shown in Table 1. Additionally, the selected drugs varied 198 
in their ionization properties (pKa) and lipophilicity (logP). Drugs with indication for 199 
gastrointestinal diseases were preferred.  200 
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Table 1: Properties and indication of selected compounds for solubility studies. 201 
Drug pKa 
(acid/base) 
















(Llinas et al., 
2008) 
Immunosuppressive 







(Bhatt et al., 
2014) 
0.028 
(Ali et al., 
2010) 
Locally acting 
corticosteroid in IBD 
Celecoxib 11.1 (acid)  
(G.D. Searle 
LLC Division 









(Paulson et al., 
2001) 
0.003 - 0.007 


























(Zaki et al., 
2010) 
 Anti-diarrheal agent 
Sulfasalazine 2.3, 7.9 (acid)  









0.29 x 10-3 
(Llinas et al., 
2008) 
Anti-inflammatory 
agent in IBD 
 202 
3.3. Solubility studies 203 
The shake-flask method was used to determine the solubility of the investigated compounds 204 
(Baka et al., 2008). Therefore, an excess amount of drug was added to 5 mL of the respective 205 
medium in a glass tube, which was then placed in a shaking water bath (Grant instruments, 206 
UK) and maintained at 37°C and 200 strokes/min for 24 h. Subsequently, GF/D membrane 207 
filters with a pore size of 2.7 μm (Whatman® Puradisc, diameter 13 mm) were used to filter the 208 
sample followed by quantitative analysis with HPLC/UV. The solubility studies were 209 
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performed in triplicate in CED disease media and healthy media and average solubility 210 
differences between CED media and healthy media were expressed as a % Relative effect on 211 
solubility [((SCED-SHealthy)/ SHealthy) x 100]. A higher drug solubility in CED media compared to 212 
healthy media is indicated by a positive value, whereas the opposite is indicated for negative 213 
values. HPLC analysis was performed with an Agilent Technologies 1200 series HPLC system 214 
(Santa Clara, CA) including a binary pump (G1212A), an autosampler (G1329A), a 215 
thermostatted column compartment (G1316A) and a diode array detector (G1315D). The 216 
methods used for the HPLC-UV analysis of the six drugs were modifications of previously 217 
published methods (presented in Gastrointestinal diseases and their impact on drug solubility: 218 
Crohn’s disease) (Effinger et al., 2020). 219 
3.4. Statistical analysis 220 
Differences between media properties and drug solubility in biorelevant media based on CED 221 
patients compared to healthy subjects were identified with the software XLSTAT (Addinsoft, 222 
France) using one-way analysis of variance (ANOVA) with a post-hoc Tukey’s test and a 223 
significance level of p≤0.05. 224 
A multifactorial ANOVA performed in Statgraphics Centurion 18 (Statpoint Technologies 225 
Inc., VA, US) was used to estimate the effects of the three categorical variables (bile salts, 226 
lecithin, cholesterol) and two-factor interactions in the DoE on the solubility of each of the six 227 
investigated compounds. Factors were considered statistically significant if the p-value was 228 
less than 0.05, indicating an effect on drug solubility at the 95.00% confidence level.  229 
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4. Results and discussion 230 
4.1. Media characterisation  231 
The surface tension of intestinal CED biorelevant media is shown in Figure 2 and was in the 232 
range of 45.5 to 51.6 mN/m and of 26.6 to 35.7 mN/m for the fasted and fed state, respectively. 233 
In the fasted state, the surface tension of all media with low bile salt concentration was higher 234 
compared to the healthy medium (p<0.05). This finding is consistent with another study, where 235 
a higher surface tension was observed for reduced bile salt concentrations in fasted state 236 
simulating fluids without cholesterol (Xie et al., 2014). Additionally, media with at the same 237 
time high bile salt and lecithin concentrations possessed a significantly higher surface tension 238 
compared to the healthy medium but a lower surface tension compared to all CED media with 239 
low bile salt concentrations (p<0.05). In the fed state, the surface tension of all CED media 240 
with low lecithin concentrations, except for the medium with at the same time low bile salt and 241 
cholesterol concentrations, was significantly decreased (p<0.05).  242 
The osmolality of biorelevant media based on CED patients and healthy subjects was not 243 
significantly different. 244 
The measured dynamic viscosities of CED biorelevant media at a shear stress of 0.06 Pa, 0.08 245 
Pa and 0.15 Pa are presented in Figure 3. All healthy and CED media showed shear thinning 246 
behaviour. The viscosity of CED biorelevant media at an applied shear stress of 0.15 Pa was 247 
in the range of 3.26 to 3.56 mPas, at 0.08 Pa in the range of 3.70 to 4.56 mPas and at 0.06 Pa 248 
in the range of 4.28 to 6.42 mPas, respectively. No significant differences between biorelevant 249 
media based on CED patients and healthy subjects were observed considering all three different 250 
shear stresses (p<0.05). 251 
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The buffer capacity was not significantly different in fasted and fed state intestinal media based 252 
on healthy subjects compared to CED patients, since the same buffer composition was used 253 
and no changes of the media pH were applied (data not shown).  254 
4.2. Solubility of drugs in CED biorelevant media 255 
Considering the final pH value of the medium after 24 h, the pH was within 6.5 ± 0.1 and 5.8 256 
± 0.1 in all cases except for the sulfasalazine studies in fasted (final medium pH: 6.2 ± 0.1) and 257 
fed state (final medium pH 5.7 ± 0.1) intestinal media. 258 
4.2.1. Neutral drugs 259 
The results of the solubility studies with neutral compounds in CED fasted and fed state 260 
intestinal media are illustrated in Figure 4.  261 
For azathioprine, the solubility in the fasted state was not significantly different in CED media 262 
compared to healthy media. In the fed state, the solubility of azathioprine was significantly 263 
higher in CED biorelevant media with high concentrations of bile salts but the relative increase 264 
was for all media below 15%. 265 
For budesonide, the solubility in all fasted state CED biorelevant media was significantly 266 
higher compared to the healthy medium (p<0.05), whereby the solubility of budesonide was 267 
highest in CED media with high bile salt concentrations. The positive effect of bile salts is in 268 
accordance with a previous study showing that an increase of the concentration of bile salts in 269 
a fixed 4:1 ratio of bile salts to lecithin resulted in an increase in budesonide solubility 270 
(Soderlind et al., 2010). Additionally, the positive effect of cholesterol on budesonide 271 
solubilisation indicates a drug-cholesterol interaction or a positive solubilisation effect of more 272 
complex vesicles (sodium taurocholate-lecithin-cholesterol) as previously reported for 273 
fenofibrate (Khoshakhlagh et al., 2015). 274 
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In the fed state, the solubility of budesonide in the CED media with at the same time low 275 
concentrations of bile salts and lecithin was significantly decreased compared to the healthy 276 
medium (p<0.05), indicating a competition for solubilisation between cholesterol and 277 
budesonide possibly due to the similarity of their chemical structure. In contrast, a significantly 278 
higher solubility was observed in CED media with high concentrations of bile salts and lecithin 279 
and CED media with either a high concentration of bile salts or lecithin and a low concentration 280 
of cholesterol (p<0.05), indicating a positive effect of higher surfactant concentration and a 281 
negative effect of cholesterol on budesonide solubility. 282 
For celecoxib, the solubility in fasted state CED media with a high concentration of lecithin 283 
and a low concentration of cholesterol was significantly higher compared to the healthy 284 
medium. In contrast, in all other CED fasted state media, the solubility of celecoxib was 285 
significantly lower (p<0.05). The positive effect of lecithin on celecoxib solubility is in 286 
accordance with previous results revealing a higher solubility of celecoxib in FaSSIF (higher 287 
concentration of lecithin) compared to FaSSIF-V2 (Shono et al., 2009).   288 
In the fed state, the solubility of celecoxib was significantly higher in CED media with at the 289 
same time high concentrations of bile salts and lecithin (p<0.05), suggesting a positive effect 290 
of luminal surfactants on celecoxib solubility. 291 
4.2.2. Weak acid 292 
The results of the solubility studies in CED fasted and fed state intestinal media with 293 
compounds possessing different ionisation properties are presented in Figure 5.  294 
For the weak acid sulfasalazine, the solubility in fasted state CED media with at the same time 295 
high concentrations of lecithin and low concentrations of cholesterol is significantly lower 296 
compared to the healthy medium (p<0.05). In fed state intestinal media, the solubility of 297 
sulfasalazine was significantly higher in CED media with high bile salt concentrations and in 298 
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the medium with a low concentration of bile salts and lecithin and a high concentration of 299 
cholesterol. 300 
4.2.3. Weak bases 301 
For the weak base dipyridamole, the solubility was significantly higher in fasted state CED 302 
media with high bile salt concentrations and to a lower extent also in the medium with a high 303 
concentration of lecithin and low concentrations of bile salts and cholesterol (p<0.05). The 304 
positive effect of bile salts on the solubility of dipyridamole is most likely the result of 305 
electrostatic interactions of the weak base with sodium taurocholate. In the fed state, the 306 
solubility of dipyridamole in the CED medium with a high concentration of lecithin and low 307 
concentrations of bile salts and cholesterol was significantly lower compared to the 308 
corresponding healthy medium (p<0.05). 309 
For loperamide hydrochloride, the solubility in the fasted state CED media with high 310 
concentrations of lecithin and cholesterol and a low concentration of bile salts was significantly 311 
lower compared to the corresponding healthy medium (p<0.05). This is possibly due to less 312 
bile salts being available for drug solubilisation due to the need for lecithin and cholesterol 313 
solubilisation. In the fed state, the solubility of loperamide hydrochloride was not significantly 314 
different in CED media compared to the corresponding healthy medium (p<0.05). 315 
4.3. Multifactorial statistical analysis of solubility in CED media 316 
For CED fasted state intestinal media, the significant effects and two-factor interactions 317 
affecting the drug solubility of the six investigated drugs are presented in Table 2.  318 
For azathioprine and budesonide, only the bile salt concentration had a positive impact on their 319 
solubility. For celecoxib, the highest positive effect on solubility was observed for the lecithin 320 
concentration, followed by a negative effect of cholesterol. Additionally, all two-factor 321 
interactions were significant for the solubility of celecoxib but less influential in comparison 322 
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to both main effects. For dipyridamole, the highest positive impact on its solubility was 323 
observed for bile salts. Other significant effects for dipyridamole were a positive effect of 324 
lecithin, a negative effect of cholesterol and the interaction between bile salts and cholesterol 325 
was significant. Considering loperamide, bile salts showed a positive and cholesterol a negative 326 
impact on solubility, respectively. For sulfasalazine solubility, a positive effect of cholesterol 327 
was observed, followed by a significant interaction of bile salts and cholesterol and a positive 328 
effect of the bile salt concentration. 329 
 330 
Table 2: Significant effects and two-factor interactions in CED fasted state intestinal media. 331 
Main effects/ 
interactions 
AZA BUD CEL DIP LOP SSZ 
BS + +  +  + + 
Lec   + +   
Chol   - - - + 
BS/Lec   -    
BS/Chol   + +  + 
Lec/Chol   -    
+: positive effect, -: negative effect, BS: bile salts, Lec: lecithin, Chol: cholesterol, AZA: 332 
azathioprine, BUD: budesonide, CEL: celecoxib, DIP: dipyridamole, LOP: loperamide, SSZ: 333 
sulfasalazine 334 
For CED fed state intestinal media, the significant effects and two-factor interactions with an 335 
impact on the drug solubility of all six drugs are shown in Table 3.  336 
For azathioprine, the bile salt concentration had the highest positive impact on solubility, 337 
followed by a positive impact of cholesterol. Considering budesonide solubility, all three main 338 
effects were significant with the highest positive impact of bile salts, followed by a positive 339 
impact of lecithin and a negative impact of cholesterol. The two-factor interactions bile 340 
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salts/cholesterol and lecithin/cholesterol were also significant but less influential compared to 341 
the main effects. For celecoxib, the lecithin concentration had the highest positive impact on 342 
its solubility, followed by a positive effect of the bile salt concentration. For dipyridamole, bile 343 
salts and cholesterol had a positive impact on solubility. Additionally, the interaction of bile 344 
salts and cholesterol was significant. Considering loperamide solubility, a negative impact of 345 
cholesterol was observed and a smaller positive effect of the lecithin concentration. For 346 
sulfasalazine, only the bile salt concentration had a positive impact on its solubility. 347 
 348 
Table 3: Significant effects and two-factor interactions in CED fed state intestinal media. 349 
Main effects/ 
interactions 
AZA BUD CEL DIP LOP SSZ 
BS +  +  +  +   + 
Lec  +  +   +  
Chol +  -   +  -  
BS/Lec       
BS/Chol  -   +   
Lec/Chol  -      
+: positive effect, -: negative effect, BS: bile salts, Lec: lecithin, Chol: cholesterol, AZA: 350 
azathioprine, BUD: budesonide, CEL: celecoxib, DIP: dipyridamole, LOP: loperamide, SSZ: 351 
sulfasalazine  352 
 353 
4.4. Drugs at risk of altered solubility in luminal fluids of CED patients 354 
For hydrophilic compounds, only small differences in drug solubility are expected between 355 
intestinal fluids of CED patients and healthy subjects as shown by the low impact of CED 356 
alterations on azathioprine solubility.  357 
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A higher impact of CED on drug solubility is expected for neutral compounds with moderate 358 
to high lipophilicity. For these drugs, a higher luminal surfactant concentration (bile salts, 359 
lecithin) is expected to result in a higher solubility. It seems to be specific to each drug whether 360 
this increase in solubility is mainly driven by bile salts as in the case of budesonide or lecithin 361 
as in the case of celecoxib.  362 
A lower risk of altered intestinal solubility in CED is expected for ionisable compounds with 363 
moderate to high lipophilicity since drug solubilisation was less impacted by CED changes 364 
integrated in the DoE compared to neutral lipophilic compounds. 365 
The investigation of solubility differences for six compounds in simulated gastrointestinal 366 
fluids representing CED patients compared to healthy subjects provided an initial 367 
biopharmaceutics risk assessment in CED patients. To reach broader conclusions a bigger 368 
database including additional compounds is needed.  369 
The present study considered differences in CED patients in terms of luminal concentrations 370 
of bile salts, lecithin and cholesterol. More studies are needed to characterise the luminal fluid 371 
composition of CED patients to investigate additional differences (e.g., luminal pH since a 372 
higher jejunal surface pH has been reported, luminal protein concentrations that are potentially 373 
increased by protein leakage through the intestinal membrane), which could not be adequately 374 
explored in this study (Kitis et al., 1982).  375 
5. Conclusion  376 
In the current study, biorelevant media developed to be representative of the small intestinal 377 
fluids in fasted and fed state of CED patients showed differences in media properties and drug 378 
solubilisation compared to biorelevant media developed based on healthy subjects. In terms of 379 
media properties, some CED media showed a higher surface tension in the fasted state 380 
compared to biorelevant media based on healthy subjects, whereas a lower surface tension was 381 
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observed in some CED media in the fed state. Differences in drug solubility in CED media 382 
compared to biorelevant media based on healthy subjects were mainly observed for moderately 383 
lipophilic compounds with a higher surfactant concentration (bile salts, lecithin) resulting in 384 
most cases in a higher drug solubility. The driving factor behind the increase in drug solubility 385 
(higher bile salt or lecithin concentration) seemed to be specific to each drug. Further solubility 386 
studies with additional compounds would increase the database for biopharmaceutics risk 387 
assessment in CED patients and additional studies investigating the composition of luminal 388 
contents in CED patients are needed. 389 
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Figure Legends 514 
Figure 1: Design of Experiments for the development of Celiac disease intestinal biorelevant 515 
media (*value observed in human intestinal fluids (Riethorst et al., 2016)). 516 
Figure 2: Surface tension (blue, left y-axis) and osmolality (rose, right y-axis) of Celiac 517 
disease biorelevant media according to the Design of Experiment (green: high level, red: low 518 
level, white: healthy) and healthy media (H). 519 
Figure 3: Dynamic viscosity of biorelevant media based on Celiac disease patients and the 520 
corresponding biorelevant media based on healthy subjects (H) at different shear stress (0.06 521 
Pa: blue, 0.08 Pa: red, 0.15 Pa: black) according to the Design of Experiments (green: high 522 
level, red: low level, white: healthy). 523 
Figure 4: % Relative effect (RE) on the solubility of neutral (at pH 5.8-6.5) investigated 524 
drugs in Celiac disease intestinal biorelevant media compared to the corresponding media 525 
based on healthy subjects according to Design of Experiments (red: low concentration of 526 
cholesterol, blue: high concentration of cholesterol, grey point: medium based on healthy 527 
subjects). 528 
Figure 5: % Relative effect on the solubility of weak acids and bases in Celiac disease 529 
intestinal biorelevant media compared to the corresponding media based on healthy subjects 530 
according to Design of Experiments (red: low concentration of cholesterol, blue: high 531 
concentration of cholesterol, grey point: medium based on healthy subjects). 532 
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